How to manage KRAS G12C-mutated advanced non-small-cell lung cancer

Constitutive KRAS signalling drives tumorigenesis across several cancer types. In non-small-cell lung cancer (NSCLC) activating KRAS mutations occur in ~30% of cases, and the glycine to cysteine substitution at codon 12 (G12C) is the most common KRAS alteration. Although KRAS mutations have been con...

Descripción completa

Detalles Bibliográficos
Autores principales: Ricciuti, Biagio, Mira, Alessia, Andrini, Elisa, Scaparone, Pietro, Michelina, Sandra Vietti, Pecci, Federica, Cantini, Luca, De Giglio, Andrea, Lamberti, Giuseppe, Ambrogio, Chiara, Metro, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677952/
https://www.ncbi.nlm.nih.gov/pubmed/36452878
http://dx.doi.org/10.7573/dic.2022-7-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677952/
https://www.ncbi.nlm.nih.gov/pubmed/36452878
http://dx.doi.org/10.7573/dic.2022-7-4

Ejemplares similares